Mental health by Busuttil, Renita & Malta Pharmaceutical Students' Association (MPSA)
dId yoU know?
German measles is also known as rubella, which is derived from Latin, meaning ‘little red.’ Rubella was initially considered to be a variant of measles or scarlet fever and was 
called ‘3rd disease’. It was not until 1814 that it was first described 
as a separate disease in the German medical literature, hence 
the common name ‘German measles’. The virus is an enveloped, 
positive-stranded RNA virus classified as a Rubivirus in the 
Togaviridae family.
In 1914, the American physician Alfred Fabian Hess 
postulated a viral etiology for German measles based on his 
work with monkeys. The Japanese scientists S. Tasaka and Y. 
Hiro in 1938 confirmed the viral etiology by passing the disease 
to children using filtered nasal washings from persons with 
acute cases.
Following a widespread epidemic of rubella infection in 
1940, Norman Gregg, an Australian ophthalmologist, reported 
in 1941 the occurrence of congenital cataracts among 78 infants 
born following maternal rubella infection in early pregnancy. 
This was the first published recognition of congenital rubella 
syndrome (CRS). Rubella virus was first isolated in 1962 by 
Parkman and Weller. The first rubella vaccines were licensed in 
1969.
Rubella became notifiable under Maltese law in 1978, and 
legal provisions for the vaccination of girls between 10 and 13 
years of age were mandated in 1989. Although CRS became 
notifiable in Malta in August 1990, only two cases were notified 
to the Department of Public Health till 1996. 
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German measles – 
why German ?
“The mentally ill frighten and embarrass us. And so we 
marginalize the people who most need our acceptance. 
What mental health needs is more sunlight, more candor, 
more unashamed conversations” 
[Glenn Close, American actress, b. 1947] 
our society is changing at a very fast rate, however unfortunately, some of our attitudes are stuck to our roots. Mentally ill people are stereotyped and 
often discriminated against. Many people are woefully 
misinformed about mental health and thus it has become 
surrounded by ignorance, prejudice and fear.
The impact of stigma is twofold. Social stigma refers 
to prejudicial attitudes and discriminating behaviour 
towards individuals with mental health problems as a 
result of the psychiatric label they have been given, e.g. 
passing a negative remark about one’s mental condition and 
treatment. Subtle discrimination involves the avoidance 
of a person suffering from mental illness because it is 
assumed that the patient could be unstable. Self-stigma is 
the internalizing thoughts and silent fears which mental 
health sufferers go through due to their own perceptions 
of discrimination and perceived stigma, turning against 
themselves.  
Therefore these patients are challenged doubly as 
they struggle with both the symptoms and complications 
that result from the disease and also the stereotypes 
and judgement that result from public humiliation and 
misconception about mental illness. This adds a greater 
burden, heavier to carry than the mental condition itself. 
Mental illness can afect anyone, in different ways. 
The stigma and discrimination associated with mental 
health can be the hardest parts of the overall experience. 
Hence, we need to make a change in our daily judgemental 
comments and change them into positive vibes which bring 
happiness and courage to one another as one can never 
know what a person is going through. 
Renita Busuttil
Medical and surgical procedure rooms are available for use in a state-of-the-art clinic in 
the most central part of B’Kara. Fully equipped, including sink, a/c and ample natural 
light. Nursing staff are available. Sharing reception facilities for appointments and all 
necessary amenities. For further enquiries please contact Mr Jesmond Cilia on 99463738.
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For patients like Maria, every day is full on, so even small reminders of 
asthma can have an impact. So, when they’re uncontrolled on ICS alone, 
choose new Relvar Ellipta:
The first ICS/LABA combination to deliver continuous 24-hour efficacy2 
In a practical, once-daily dose1
Delivered in an easy to use device that patients prefer to their
current inhaler3,4*
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Relvar Ellipta (ﬂ uticasone furoate/vilanterol) Abridged Prescribing 
Information
 This medicinal product is subject to additional monitoring. This will allow 
quick identiﬁ cation of new safety information. Healthcare professionals are 
asked to report any suspected adverse reactions. See section 4.8 on SPC how 
to report adverse reactions.
Please refer to the full Summary of Product Characteristics before prescribing
Trade Name: RELVAR ELLIPTA. Active Ingredients: 92 micrograms or 
184 micrograms of ﬂ uticasone furoate and 22 micrograms of vilanterol 
(as trifenatate). Pharmaceutical Form: 92  micrograms/22  micrograms or
184 micrograms/22 micrograms inhalation powder, pre-dispensed. 
Indications: The 92 micrograms/22 micrograms dose: for the regular 
treatment of asthma in adults and adolescents aged 12 years and older where 
use of a combination medicinal product (long-acting beta2-agonist and 
inhaled corticosteroid) is appropriate; and for the symptomatic treatment of 
adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) 
with an exacerbation history despite regular bronchodilator therapy. The 
184 micrograms/22 micrograms dose: for the regular treatment of asthma in 
adults and adolescents aged 12 years and older where use of a combination 
medicinal product (long-acting beta2-agonist and inhaled corticosteroid) 
is appropriate. Dosage and Method of Administration: For Athsma: One 
inhalation of Relvar Ellipta 92/22 micrograms or 184/22 micrograms once 
daily. Patients usually experience an improvement in lung function within 
15 minutes of inhaling Relvar Ellipta. However, the patient should be 
informed that regular daily usage is necessary to maintain control of asthma 
symptoms and that use should be continued even when asymptomatic. If 
symptoms arise in the period between doses, an inhaled, short-acting beta2-
agonist should be taken for immediate relief. A starting dose of Relvar 
Ellipta 92/22 micrograms should be considered for adults and adolescents 12 
years and over who require a low to mid dose of inhaled corticosteroid in 
combination with a long-acting beta2-agonist. If patients are inadequately 
controlled on Relvar Ellipta 92/22 micrograms, the dose can be increased to 
184/22 micrograms, which may provide additional improvement in asthma 
control. For COPD: One inhalation of Relvar Ellipta 92/22 micrograms once 
daily. Relvar Ellipta 184/22 micrograms is not indicated for patients with 
COPD. Relvar Ellipta is for inhalation use only. It should be administered at 
the same time of the day, each day. Contraindications: Hypersensitivity to 
the active ingredient or excipients. Precautions for Use: Fluticasone furoate/
vilanterol should not be used to treat acute asthma symptoms, for which 
a short-acting bronchodilator is required. Caution in severe cardiovascular 
disease, moderate-to-severe hepatic impairment, pulmonary tuberculosis 
or in patients with chronic or untreated infections, history of diabetes 
mellitus and for paradoxical bronchospasm and pneumonia in patients with 
COPD. Drug Interactions: Beta-blockers, CYP3A4 inhibitors, P-glycoprotein 
inhibitors and sympathomimetic medicinal products (refer to the full 
Summary of Product Characteristics for list of drugs). Fertility, Pregnancy and 
Lactation: Pregnancy: No adequate data available. Lactation: insufﬁ cient 
information available. Fertility: There is no data in humans. Animal studies 
indicate no effect on fertility. Effect on Ability to Drive or Use Machines: 
No or negligible inﬂ uence. Undesirable Effects: Very common side effects 
include headache and nasopharyngitis (refer to the full Summary of Product 
Characteristics for complete list of undesirable effects). Overdose: There is no 
speciﬁ c antidote. Treatment of overdose should consist of general supportive 
measures. Local Presentations: Relvar Ellipta 92 micrograms/22 micrograms 
inhalation powder, pre-dispensed and Relvar Ellipta 184 micrograms/
22 micrograms inhalation powder, pre-dispensed. Legal Category: POM. 
Marketing Authorisation Holder: Glaxo Group Limited, 980 Great West Road, 
Brentford, Middlesex TW8 9GS, United Kingdom Marketing Authorisation 
Numbers: EU/1/13/886/001-6 DATE OF PREPARATION: December 2013
In order to ensure that this product information reﬂ ects the mos
up-to-date clinical and post-marketing surveillance data, please always refer 
to the latest Summary of Product Characteristics (SPC) which is available 
from GlaxoSmithKline (Malta) Ltd (Tel: +356 21238131)
REPORTING ADVERSE EVENTS (AEs):
Malta & Gibraltar: If you become aware of any AEs, medication errors and/or 
use during pregnancy in association with GSK products, please report the event 
promptly to: GSK (Malta) Limited, 1, De la Cruz Avenue, Qormi QRM 2458, Malta 
(Tel: +356 21238131)
Malta: alternatively, any suspected AEs and medication errors can also be reported 
via the national Adverse Drug Reactions (ADRs) reporting system
Report forms can be downloaded from www.medicinesauthority.gov.mt/adrportal 
and posted to the Malta Medicines Authority, Post-licensing Directorate, 203, 
Level 3, Rue D’Argens, Gżira GŻR 1368, MALTA, or sent by email to postlicensing.
medicinesauthority@gov.mt
Gibraltar: alternatively, any suspected AEs and medication errors can also be 
reported via the UK regulatory authority (MHRA): https://yellowcard.mhra.gov.uk/
*Patients’ current or previous maintenance inhalers: HandiHaler/ DISKUS/ MDI/ HFA (COPD); 
DISKUS/ MDI/ HFA (asthma).4
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